All Times EDT
Legend:
Activity Details
193
Tue, 8/4/2020,
10:00 AM -
2:00 PM
Virtual
Modeling, Design Strategies and Assessments of Biomarkers — Contributed Papers
Biopharmaceutical Section
Chair(s): Gitanjali Paul, GlaxoSmithKline plc
Visualizing Biomarkers and Their Association with Clinical Outcomes: A Machine Learning Approach
Hui Zheng, Harvard Medical School
Modeling Count Data with Extreme High Counts
Ping Xu, Merck & Co Inc ; Qing Li, Merck Research Labs; Anjela Tzontcheva, Merck & Co., Inc; Ruji Yao, Merck; Guanghan Frank Liu, Merck Inc.
A Three-Stage Deep Learning Method for Biomarker Identification from Gene Expression Data and Baseline Disease Activities
Bochao Jia
Effect of Tumor Size Change and Duration of Response on Overall Survival in Immunotherapy Trials
Meihua Wang, Merck & Co. ; Jing Yang, Merck & Co.; Iris Wu, Merck; Heng Zhou, Merck; Cong Chen, Merck and Company, Inc.
Issues and Solutions in Biomarker Evaluation When Sub-Classes Are Involved Under Binary Classification
Yingdong Feng, Eli Lilly & Company ; Lili Tian, University at Buffalo
A Linear Mixed Effects Model with Censored Response for Longitudinal Biomarker Data Subject to Lower Limits of Detection
Xueli Liu, AbbVie Inc. ; Chun Zhang, AbbVie Inc.
Estimation and Construction of Confidence Intervals for the Cutoff-Points of Continuous Biomarkers in Trichotomous Settings
Brian Mosier, University of Kansas Medical Center ; Leonidas Bantis, University of Kansas Medical Center
Should We Check the Normality? The Impact of Model Assumptions in Early Phase Clinical Studies
Qianyu Dang, FDA Center for Drug Evaluation and Research (CDER) ; Ran Bi, FDA/HHS
Assessment of Predictive Biomarkers for Vaccine Development
Ivan David Ordonez, Sanofi Pasteur ; Robert D Small, Dr.; Maïna L’Azou, Sanofi Pasteur; Edith Langevin, Sanofi Pasteur; Pauline Jurvilliers, Sanofi; Darin Edwards, Moderna Therapeutics
